(Q80213802)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

The second international meeting on allogeneic transplantation in solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Bregni M

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Ueno NT

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Childs R

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

4 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

527-537

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16953213%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705479

29 December 2019

exact match

0 references

cites work

Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021

Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705479

7 January 2021